A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple ...

Doctors are looking to recruit more people for the trial, which they say could one day be given as a single one-off treatment ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

An event like this takes significant planning, teamwork, and collaboration to provide a safe and successful ride. The ...

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells ...

Scientists have found that people with multiple sclerosis (MS) have a distinctly imbalanced oral microbiome—marked by a loss of beneficial bacteria and a rise in inflammation-linked microbes.

A multiple sclerosis (MS) patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a ...

TG Therapeutics (($TGTX)) announced an update on their ongoing clinical study. Study Overview: TG Therapeutics is conducting a Phase 3 study ...

With ads everywhere for pro- or pre-biotic foods and supplements, most people are familiar with the gut microbiome—the ...

Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of fenebrutinib, and bone marrow transplantation as an effective long-term treatment.

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...